4.3 Review

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

Journal

TRANSLATIONAL ANDROLOGY AND UROLOGY
Volume 7, Issue 5, Pages 831-843

Publisher

AME PUBL CO
DOI: 10.21037/tau.2018.08.03

Keywords

Positron emission tomography/computed tomography (PET/CT); nuclear medicine; prostatic neoplasms; tomography; emission-computed, single-photon; gallium

Funding

  1. Intramural Research Program of the National Institutes of Health
  2. National Cancer Institute, National Institutes of Health [HHSN261200800001E]
  3. NATIONAL CANCER INSTITUTE [ZIABC010655] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) is an emerging prostate cancer imaging method, which has been reported to have a higher sensitivity and specificity than the currently approved PET imaging agents. Multiple PSMA ligands are being investigated around the world and applications range from primary tumor characterization, to local staging, biochemical recurrence, metastasis, and image-guided interventions. The most investigated PET tracers are labelled with 68-Gallium or 18-Fluoride and are discussed in this review. Additionally, Tc-99m labeled PSMA agents for single photon emission computed tomography (SPECT) imaging are elucidated as an alternative method of PSMA image acquisition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available